Genmab — August 2020
-
Dejlig artikel, tak for den butterboy
-
GEN1044 (DuoBody
-CD3x5T4) started recruiting in July https://www.clinicaltrials.gov/ct2/history/NCT04424641?A=1&B=2&C=merged#StudyPageTop -
GEN1046 still steadily adding locations, all recruiting https://www.clinicaltrials.gov/ct2/history/NCT03917381?A=9&B=10&C=merged#StudyPageTop
-
Enapotamab almost all recruiting as well https://www.clinicaltrials.gov/ct2/history/NCT02988817?A=16&B=17&C=merged#StudyPageTop
-
Mht epcoritamab, så tåler denne genlæsning. “Jeg har aldrig set så potent et lægemiddel til den her type patienter“ og “ lige så effektiv som CART-T og mere sikker” https://haematologisktidsskrift.dk/sygdomme/lymfoma/720-subkutant-bispecifikt-cd3-cd20-antistof-mulig-konkurrent-til-car-t.html
-
puha Darvin det er jo NSFW materiale du deler der
-
De omtaler ikke den okulare toksicitet https://haematologisktidsskrift.dk/sygdomme/myeloma/739-dansk-optimisme-efter-ema-godkendelse-af-ny-myelomatose-behandling.html
-
Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs https://investors.immatics.com/news-releases/news-release-details/immatics-announces-european-clinical-expansion-its-adoptive-cell
-
Immatics’ clinical product class ACTengine
is a personalized approach for patients with advanced solid cancers. Patient’s own T cells are genetically modified to express a novel proprietary TCR cognate to one of Immatics’ cancer targets identified by its proprietary XPRESIDENT target discovery platform. -
No news yet from ADCT "Announced FDA lifted partial clinical hold on pivotal Phase 2 trial of Cami for relapsed or refractory Hodgkin lymphoma: In July 2020, the Company announced that the FDA had lifted the partial clinical hold on its pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami, formerly ADCT-301) in patients with relapsed or refractory Hodgkin lymphoma (HL).
-
The Company continued to treat those patients who could benefit from ongoing treatment during the partial clinical hold, and the clinical trial is now open for enrollment. Interim results from the clinical trial are expected in the first half of 2021, subject to any impact by COVID-19. The clinical trial is intended to support the submission of a BLA to the FDA."
derfor mit ?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind